Cancer Drug Patent Rejected In India

By  | 

A lawyer for healthcare activists says India's Supreme Court has rejected drug maker Novartis AG's right to patent a new version of a lifesaving cancer drug.

The landmark ruling Monday is a victory for India's $26 billion generic drug industry that provides cheap medicines to millions around the world.

The ruling is a precedent that prevents international pharmaceutical companies from obtaining fresh patents in India on updated versions of existing drugs.

Lawyer Anand Grover said such a ruling would help poor people get access to affordable, generic versions of lifesaving medicines.

Novartis has fought a legal battle in India since 2006 for a fresh patent for a leukemia drug.

India's patent office had rejected the company's patent application because it was not a new medicine.


We encourage commenting on our stories to give you a chance to express your opinion. We rely upon the online community to report abuse. Repeat violators may be banned from posting comments. CLICK HERE for the guidelines for posting comments. powered by Disqus